Drugs used to immobilize patients during surgery raises risk of respiratory complications

October 16, 2012

Massachusetts General Hospital (MGH) researchers have found that medications currently used to immobilize patients during surgery can increase the risk of postoperative respiratory complications. Their study being published online in the journal BMJ also found that the agent most commonly used to reverse the action of the immobilizing drug does not prevent and may possibly increase the risk that patients will need to receive postoperative respiratory support.

"Neuromuscular blocking agents are used during surgery for a variety of reasons, including allowing placement of a and preventing patients from moving during a procedure, says Matthias Eikermann, MD, PhD, director of Research in the Critical Care Division of the MGH Department of Anesthesia, Critical Care and , senior author of the report. "Unfortunately, these agents do not stop working immediately at the end of surgery, leading to residual muscle weakness which can decrease postoperative respiratory function. Our findings suggest that we need to develop better blocking agents and improved methods of monitoring their effects."

Drugs that prevent transmission of signals from nerves to muscles are commonly used in and in on mechanical ventilators. Long-acting neuromuscular blocking agents can increase the risk of , so in recent years they have been replaced with newer, intermediate-acting drugs. Eikermann's team focuses on developing new strategies in general anesthesia that can stablize and improve respiratory function. Their previous work suggested that intermediate-acting agents may be responsible for a high incidence of in patients recovering from surgery, leading to respiratory difficulties that lengthen a patient's time in the recovery room. The current study analyzed data on surgeries involving conducted at the MGH from March 2006 to September 2010.

The researchers compared data on more than 20,000 surgeries in which intermediate-acting neuromuscular blocking agents were used with an equal number of procedures that did not use the drugs, looking at recordings of patients' blood oxygen levels after the removal of breathing tubes and whether it became necessary to replace a breathing tube within 72 hours of surgery, a procedure requiring intensive care unit admission. They also analyzed the strategies used to monitor neuromuscular function during surgery and whether a drug was administered that reverses the action of the immobilization agent.

Their results showed that patients who received intermediate-acting neuromuscular blocking agents had a 40 percent greater risk of requiring reintubation because of low blood oxygen levels. Functional monitoring of neuromuscular strength by means of visual or tactile assessment of muscular response to an electric stimulus had no significant effect on risk, but the use of the reversal agent neostigmine made the risk of reintubation even greater. Eikermann notes that patients with postoperative respiratory complications have a significantly greater risk of death than those without complications.

"Both neuromuscular blocking agents and the blocker-reversing agent currently used have important roles in perioperative medicine. But these medications have a narrow therapeutic range and can have dangerous, unintended effects on the respiratory system," says Eikermann, an associate professor of Anaesthesia at Harvard Medical School. "The best way to reduce these risks will be the development and use of shorter-acting neuromuscular blockers and new reversal agents that directly halt the effects of blocking agents." He and his team are currently evaluating new reversal agents and interventions for preventing perioperative respiratory complications.

Eikermann adds that the use of monitoring equipment that can quantitatively measure neuromuscular function, instead of the current qualitative estimates, should more accurately reflect drug action, giving the kind of precise data required to standardize procedures. His team is developing clinical strategies to implement the type of monitoring that will help anesthesia providers more appropriately dose and time the administration of these powerful, necessary drugs.

Explore further: Anesthesia regimen linked to post-orthognathic op pain

Related Stories

Anesthesia regimen linked to post-orthognathic op pain

July 31, 2012
(HealthDay) -- Patients undergoing orthognathic maxillofacial surgery experience more pain postoperatively if they receive anesthesia with propofol and remifentanil versus inhalational agents and longer-acting opioids, according ...

Postoperative program prevents respiratory complications: study

October 4, 2012
(HealthDay)—A simple and inexpensive program can reduce the risk of life-threatening and costly respiratory complications that are common after surgery, according to a new study.

Review of multilevel surgery in patients with obstructive sleep apnea

March 19, 2012
Patients with obstructive sleep apnea who undergo surgery for their condition should be closely monitored after their procedures are performed but may not need to be in an intensive care unit, according to a report published ...

Common stimulant may speed recovery from general anesthesia

September 21, 2011
Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital (MGH). The report, appearing in ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.